---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-044909"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2024-04-09T23:59:59+00:00"
generated_at: "2026-06-04T01:07:06.051379+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics presents novel iPSC-derived cell therapy preclinical data at AACR 2024

## Summary
- CD19xCD22 bispecific CAR showed cytotoxicity against CD19/CD22 tumor cells in vitro and in xenograft models.
- Allo-Evasion platform: combining HLA-E and HLA-G offered best protection against NK-mediated rejection of iPSC-derived cells.
- NECTIN4-targeted iPSC-derived CAR-T demonstrated tumor inhibition comparable to Enfortumab-based CAR in OVCar-3 xenografts.
- CXCR4 transgene in iPSC-derived NK cells enhanced migration and anti-tumor efficacy in vivo, eliminating bone disease.
- Novel inhibitory CAR targeting DSG1 designed to reduce off-tumor skin toxicity of NECTIN4 therapy.

## SEC filing metadata
- accession: 0001104659-24-044909
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2024-04-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465924044909/0001104659-24-044909-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465924044909/tm2411338d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-044909
- JSON: https://secwatch.observer/filing/0001104659-24-044909.json
- Plain text: https://secwatch.observer/filing/0001104659-24-044909.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.